Happy Thanksgiving! Save 50% on Your MarketBeat All Access Subscription.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Walmart shooter left 'death note,' bought gun day of killing
See how to make money instead of spending it on Black Friday with this offer (Ad)
US stocks wobble to a mixed close, indexes keep weekly gains
Arrival, Coupa Software rise; Apple, Activision fall
THE BEST BLACK FRIDAY DEAL YET (Ad)
New this week: Lizzo, 'Criminal Minds' and 'The Woman King'
Police: Walmart shooter bought gun just hours before killing
THE BEST BLACK FRIDAY DEAL YET (Ad)
Musk says granting 'amnesty' to suspended Twitter accounts
Musk plans to relaunch Twitter premium service, again
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Walmart shooter left 'death note,' bought gun day of killing
See how to make money instead of spending it on Black Friday with this offer (Ad)
US stocks wobble to a mixed close, indexes keep weekly gains
Arrival, Coupa Software rise; Apple, Activision fall
THE BEST BLACK FRIDAY DEAL YET (Ad)
New this week: Lizzo, 'Criminal Minds' and 'The Woman King'
Police: Walmart shooter bought gun just hours before killing
THE BEST BLACK FRIDAY DEAL YET (Ad)
Musk says granting 'amnesty' to suspended Twitter accounts
Musk plans to relaunch Twitter premium service, again
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Walmart shooter left 'death note,' bought gun day of killing
See how to make money instead of spending it on Black Friday with this offer (Ad)
US stocks wobble to a mixed close, indexes keep weekly gains
Arrival, Coupa Software rise; Apple, Activision fall
THE BEST BLACK FRIDAY DEAL YET (Ad)
New this week: Lizzo, 'Criminal Minds' and 'The Woman King'
Police: Walmart shooter bought gun just hours before killing
THE BEST BLACK FRIDAY DEAL YET (Ad)
Musk says granting 'amnesty' to suspended Twitter accounts
Musk plans to relaunch Twitter premium service, again
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Walmart shooter left 'death note,' bought gun day of killing
See how to make money instead of spending it on Black Friday with this offer (Ad)
US stocks wobble to a mixed close, indexes keep weekly gains
Arrival, Coupa Software rise; Apple, Activision fall
THE BEST BLACK FRIDAY DEAL YET (Ad)
New this week: Lizzo, 'Criminal Minds' and 'The Woman King'
Police: Walmart shooter bought gun just hours before killing
THE BEST BLACK FRIDAY DEAL YET (Ad)
Musk says granting 'amnesty' to suspended Twitter accounts
Musk plans to relaunch Twitter premium service, again
NASDAQ:AKTX

Akari Therapeutics - AKTX Stock Forecast, Price & News

$0.57
-0.01 (-1.73%)
(As of 11/25/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.50
$0.58
50-Day Range
$0.40
$0.67
52-Week Range
$0.38
$1.70
Volume
21,084 shs
Average Volume
78,811 shs
Market Capitalization
$42.22 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.00

Akari Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
605.3% Upside
$4.00 Price Target
Short Interest
Healthy
0.05% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.77mentions of Akari Therapeutics in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.20 out of 5 stars

Medical Sector

384th out of 1,044 stocks

Pharmaceutical Preparations Industry

178th out of 508 stocks

AKTX stock logo

About Akari Therapeutics (NASDAQ:AKTX) Stock

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid. Akari Therapeutics, Plc is based in London, the United Kingdom.

Receive AKTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Akari Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

AKTX Stock News Headlines

Akari Therapeutics Plc - ADR
Short Volatility Alert: AKARI THERAPEUTICS
Akari Therapeutics, Plc (AKTX)
Akari Therapeutics Narrows Pipeline Focus
See More Headlines
Receive AKTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Akari Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

AKTX Company Calendar

Last Earnings
9/27/2022
Today
11/26/2022
Next Earnings (Estimated)
12/02/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AKTX
Employees
9
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$4.00
High Stock Price Forecast
$4.00
Low Stock Price Forecast
$4.00
Forecasted Upside/Downside
+605.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-17,420,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.11 per share

Miscellaneous

Free Float
28,440,000
Market Cap
$42.22 million
Optionable
Not Optionable
Beta
1.28

Key Executives

  • Dr. Ray Prudo-Chlebosz M.D. (Age 77)
    Exec. Chairman
    Comp: $618k
  • Dr. Torsten Hombeck (Age 52)
    Chief Financial Officer
    Comp: $454.88k
  • Ms. Rachelle Suzanne Jacques (Age 51)
    Pres, CEO & Director
  • Ms. Melissa Bradford-Klug
    Chief Operating Officer
  • Dr. Miles Nunn
    Chief Scientific Officer
  • Annie Mack
    Financial Controller













AKTX Stock - Frequently Asked Questions

Should I buy or sell Akari Therapeutics stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Akari Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AKTX shares.
View AKTX analyst ratings
or view top-rated stocks.

What is Akari Therapeutics' stock price forecast for 2023?

1 analysts have issued 1-year price targets for Akari Therapeutics' shares. Their AKTX share price forecasts range from $4.00 to $4.00. On average, they predict the company's share price to reach $4.00 in the next twelve months. This suggests a possible upside of 605.3% from the stock's current price.
View analysts price targets for AKTX
or view top-rated stocks among Wall Street analysts.

How have AKTX shares performed in 2022?

Akari Therapeutics' stock was trading at $1.50 at the start of the year. Since then, AKTX stock has decreased by 62.2% and is now trading at $0.5671.
View the best growth stocks for 2022 here
.

When is Akari Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, December 2nd 2022.
View our AKTX earnings forecast
.

How were Akari Therapeutics' earnings last quarter?

Akari Therapeutics, Plc (NASDAQ:AKTX) announced its quarterly earnings data on Tuesday, September, 27th. The biopharmaceutical company reported ($0.10) EPS for the quarter.

What other stocks do shareholders of Akari Therapeutics own?
What is Akari Therapeutics' stock symbol?

Akari Therapeutics trades on the NASDAQ under the ticker symbol "AKTX."

Who are Akari Therapeutics' major shareholders?

Akari Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Armistice Capital LLC (5.76%) and Omnia Family Wealth LLC (1.05%).
View institutional ownership trends
.

How do I buy shares of Akari Therapeutics?

Shares of AKTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Akari Therapeutics' stock price today?

One share of AKTX stock can currently be purchased for approximately $0.57.

How much money does Akari Therapeutics make?

Akari Therapeutics (NASDAQ:AKTX) has a market capitalization of $42.22 million. The biopharmaceutical company earns $-17,420,000.00 in net income (profit) each year or ($0.35) on an earnings per share basis.

How can I contact Akari Therapeutics?

Akari Therapeutics' mailing address is 75/76 WIMPOLE STREET, LONDON X0, W1G 9RT. The official website for the company is www.akaritx.com. The biopharmaceutical company can be reached via phone at 442080040261, via email at info@akaritx.com, or via fax at 646-843-9352.

This page (NASDAQ:AKTX) was last updated on 11/26/2022 by MarketBeat.com Staff